Gut microbiota dysbiosis and the gut–lung axis in COPD: mechanisms, clinical relevance, and microbiota-targeted interventions Authors: Yinghui Chai, Junya Lan, Kang Li, Xue Mei, Yanan Chen, Nannan Zhou, Xin Liu, Wenping Gong, Hong Lei Published: 2026 ABSTRACT Chronic obstructive pulmonary disease (COPD), which is characterised by persistent inflammation and airflow limitation, has increasingly been linked to the gut-lung axis. Patients with COPD commonly exhibit reduced diversity of gut microbiota, decreased levels of bacteria that produce short-chain fatty acids (SCFAs), increased levels of opportunistic pathogens, and compromised intestinal barrier function. These alterations are driven by factors such as smoking, hypoxia, oxidative stress, medication use and ageing, and promote bacterial translocation and systemic inflammation, thereby exacerbating lung injury. Gut microbiota metabolites, including SCFAs, bile acids, tryptophan metabolites and trimetlylamine N-oxide (TMAO), further modulate immune responses and metabolic pathways, thereby influencing disease progression. Intervention strategies targeting the microbiome, including dietary fibre, probiotics, prebiotics, faecal microbiota transplantation (FMT) and phage therapy, have demonstrated potential therapeutic value, though clinical evidence remains limited. Elucidating the mechanisms linking gut dysbiosis and COPD will provide novel targets for precision interventions and disease management. Introduction Chronic obstructive pulmonary disease (COPD) is a significant global health issue that poses a serious challenge to public health. The primary characteristic of COPD is airflow limitation, which is usually progressive and irreversible (Liu C, et al., 2022). As the global population ages, COPD-related frailty has also become a hot topic in research. Despite advances in current therapeutic strategies, available treatments mainly alleviate symptoms and reduce exacerbations but have limited effects on halting disease progression or correcting the underlying pathophysiological mechanisms. Furthermore, COPD is heterogeneous, encompassing numerous subtypes and phenotypes that reflect distinct pathophysiological mechanisms (Zhu et al., 2020). As hallmark features of COPD, smoking and airflow limitation are not only major risk factors for disease progression (Kapellos et al., 2023), but also frequently the primary drivers of the aforementioned unmet needs. Current standard treatment strategies, including smoking cessation, bronchodilator therapy, pulmonary rehabilitation and vaccination, improve clinical outcomes (Traboulsi et al., 2020; Matsunaga et al., 2019). However, comorbid conditions such as asthma, bronchiectasis and cardiovascular disease are closely associated with COPD’s clinical heterogeneity and may contribute to suboptimal responses to standard therapies (Chen Q. et al., 2025). Furthermore, additional pathogenic mechanisms and potential therapeutic targets remain to be identified, prompting increasing interest in the role of the gut–lung axis in COPD. Bronchial obstruction is a key point in COPD treatment, and microorganisms are closely associated with the onset and progression of COPD (Nauck et al., 2024; Zhu et al., 2023). Microorganisms are frequently detectable in the airways of COPD patients, both during stable periods and acute exacerbations (Tiew et al., 2022). Isolation of potential pathogenic microorganisms (PPMs) such as Haemophilus influenzae, Streptococcus pneumoniae, or Pseudomonas aeruginosa from respiratory specimens does not meet the definition of colonization, as these microorganisms are associated with tissue damage and inflammatory responses (Feng et al., 2023). Increasing evidence suggests that modulation of the gut microbiota may represent a potential avenue for improving COPD management through the gut–lung axis, although the underlying mechanisms and clinical applications require further investigation and validation. Recent studies have increasingly focused on the role of gut microbiota in COPD. Emerging evidence indicates that patients with COPD exhibit gut microbiota dysbiosis, characterized by altered microbial composition and reduced microbial diversity (Li et al., 2026), which has been associated with disease severity and progression. Research suggests that gut microbiota and their metabolites are closely associated with the development and progression of various diseases, and their link to pulmonary disorders is referred to as the gut-lung axis (Zhang et al., 2025; Liu et al., 2024). In COPD, gut microbiota may influence disease progression by altering the integrity of the intestinal barrier, producing pro-inflammatory metabolites and modulating bone marrow haematopoietic and immune functions (Wang et al., 2023). Gut microbiota and their metabolites may contribute to the inflammatory and immune responses in COPD (Song et al., 2023), although the precise mechanisms are not fully understood. Experimental studies further support gut microbiota as a potential therapeutic target in COPD. Experimental studies using faecal microbiota transplantation (FMT) have demonstrated a causal relationship between gut microbiota and COPD, as transplantation of faecal microbiota from COPD patients accelerated disease progression in mice (Jia et al., 2022). FMT from patients with advanced COPD induced COPD-like inflammatory responses, airway remodelling and lung function deterioration in experimental models (Lim et al., 2023). These findings confirm the role of gut microbiota as a pathogenic factor in COPD. Conversely, FMT from healthy donors alleviated pulmonary inflammation and improved lung function in COPD models (Lim et al., 2023). Taken together, these results suggest that gut microbiota may play a role in COPD development and treatment, providing new insights for clinical management and therapeutic approaches. This review summarizes current evidence regarding gut microbiota dysbiosis in COPD, the underlying mechanisms of the gut–lung axis and emerging microbiota-targeted therapeutic strategies. The impact of COPD on gut microbiota COPD leads to an imbalance in gut microbiota diversity and structure The diversity and structural imbalance of the gut microbiota in patients with COPD have been extensively studied, particularly in terms of alpha and beta diversity. Studies indicate that, compared to healthy controls, COPD patients exhibit reduced diversity of the gut microbiota and significant structural differences (Li K. et al., 2025; Kotlyarov, 2023). This decrease in diversity may be associated with acute COPD exacerbations (Ma et al., 2021), suggesting that alterations in gut microbiota structure could be linked to them. In terms of α-diversity, the species richness and evenness of the gut microbiota were both lower in COPD patients than in the control group. β-Diversity analysis revealed compositional differences between COPD patients and healthy individuals, which may reflect variations in the structure of the gut microbiota at an individual level (Ditz et al., 2020). Additionally, changes in the abundance of Bacteroides species and a reduction in Clostridium perfringens within the gut microbiota of COPD patients may be associated with the onset and progression of the disease (Lai et al., 2024). This dysbiosis may contribute to COPD severity through systemic inflammatory responses (Luo et al., 2025). These findings indicate that gut microbiota dysbiosis is closely associated with COPD development and progression. Similar alterations have also been reported in other chronic inflammatory diseases, particularly inflammatory bowel disease (IBD). In IBD, reduced microbial diversity, depletion of Firmicutes, enrichment of Enterobacteriaceae, impaired epithelial barrier function and increased mucosal permeability contribute to persistent intestinal inflammation (Wang et al., 2021; Covello et al., 2024; Pedroza Matute and Iyavoo, 2023). These findings further support the importance of maintaining microbial homeostasis in chronic inflammatory diseases. Reduced gut microbial diversity and depletion of short-chain fatty acid (SCFA)-producing bacteria are common findings in patients with COPD. However, changes in specific bacterial taxa have been less consistent. For instance, studies have reported different patterns in the abundance of Bacteroides and Prevotella (Li et al., 2026; Wang et al., 2026; Cheng and Zhang, 2024). These variations are likely related to differences in study design, patient characteristics (e.g., stable COPD versus AECOPD), disease severity, sequencing methodologies (16S rRNA sequencing versus shotgun metagenomic sequencing), and data analysis approaches. Therefore, findings on individual bacterial taxa should be interpreted within the context of each study, and future research using standardized protocols and longitudinal designs is needed to better characterize gut microbiota alterations associated with COPD. Association between clinical phenotypes and gut microbiota in COPD patients The clinical phenotypes of COPD patients vary according to the severity of their condition and how they present their symptoms. Studies reveal that the status of the gut microbiota of patients in the stable phase of COPD is closely associated with inflammatory markers and pulmonary function (Chenery et al., 2021). Studies have shown that the gut microbiota of COPD patients correlates with the level of airway inflammation (Halpin, 2022). Furthermore, distinct gut microbiota structures are observed in COPD patients between the acute exacerbation phase and the stable phase (Hu et al., 2023). During acute exacerbations, the relative abundance of Firmicutes and Actinobacteria decreases, while that of Bacteroidetes and Proteobacteria increases (Enaud et al., 2023). These findings suggest that disease exacerbation is accompanied by dynamic alterations in gut microbial composition. The composition of the gut microbiota of COPD patients differs significantly from that of healthy individuals (Kotlyarov, 2022). Studies indicate that COPD patients exhibit characteristic alterations in gut microbial composition, including decreased levels of Lactobacillus and Bifidobacterium and increased levels of Enterococcus and Prevotella (Lu et al., 2024). This dysbiosis is closely associated with impaired lung function in COPD patients (Jia et al., 2022). Specifically, the abundance of Lactobacillus and Bifidobacterium correlates positively with forced expiratory volume in one second (FEV1), FEV1 as a percentage of predicted value (FEV1%pred), and the FEV1/forced vital capacity (FEV1/FVC) ratio. Conversely, the abundance of Enterococcus and Prevotella correlates negatively with these pulmonary function metrics (Li et al., 2023; Meng et al., 2024). These findings support an association between gut microbial alterations and impaired pulmonary function within the framework of the gut–lung axis. Patients with COPD frequently experience multiple comorbidities, including cardiovascular disease, diabetes, anxiety and depression (Aldibbiat and Al-Sharefi, 2020). These conditions worsen the patient’s disease state and negatively impact quality of life and prognosis (Park et al., 2024). Research indicates that gut dysbiosis in COPD patients is closely linked to the onset and progression of these comorbidities (Jundi et al., 2023). For example, elderly COPD patients with a high Charlson Comorbidity Index (CCI) are more likely to have gut dysbiosis, suggesting that multiple coexisting diseases can exacerbate intestinal microbial imbalance (Bogdan et al., 2023). This dysbiosis may contribute to the development of these comorbidities through immune and metabolic dysregulation (Mac Aogáin et al., 2023). The composition of the gut microbiota also varies among COPD patients with different comorbidities. For example, COPD patients with diabetes have significantly lower levels of Bifidobacteria and Lactobacilli in their intestines, while levels of Enterococcus and Escherichia coli increase (Dahal et al., 2023). This may be related to metabolic disturbances and altered immune function caused by diabetes. Furthermore, COPD patients with cardiovascular disease exhibit markedly reduced gut microbiota diversity, which is associated with elevated inflammatory factor levels (Yu et al., 2024). These studies suggest that different comorbidities may influence the gut microbiota of COPD patients via distinct mechanisms, thereby further impacting disease progression (Table 1). TABLE 1Gut microbiota alterations in different clinical states of COPD.Clinical phenotypeGut microbiota characteristicsClinical significanceReferencesHealthy controlsHigher microbial diversity; balanced microbial compositionReferences microbiota profile Yang et al. (2026) Stable COPDReduced α-diversity; decreased Lactobacillus and Bifidobacterium; increased Enterococcus and PrevotellaAssociated with impaired pulmonary function and chronic systemic inflammation Jia et al. (2022); Lu et al. (2024) Acute exacerbation COPD (AECOPD)Reduced Firmicutes and Actinobacteria; increased Bacteroidetes and ProteobacteriaAssociated with enhanced inflammatory responses and disease exacerbation Enaud et al. (2023) COPD with diabetesReduced Bifidobacterium and Lactobacillus; increased Enterococcus and Escherichia coliMay contribute to metabolic dysregulation and immune imbalance Dahal et al. (2023) COPD with cardiovascular diseaseReduced microbial diversityAssociated with elevated systemic inflammatory markers Yu et al. (2024) Abbreviations: COPD, chronic obstructive pulmonary disease; AECOPD, acute exacerbation of chronic obstructive pulmonary disease. Gut microbiota alterations in different clinical states of COPD. Abbreviations: COPD, chronic obstructive pulmonary disease; AECOPD, acute exacerbation of chronic obstructive pulmonary disease. COPD drives changes in the gut microbiota COPD patients frequently exhibit systemic hypoxia and oxidative stress, with markedly elevated levels of oxidative stress markers—such as hydrogen peroxide and eight-isoprostane—in exhaled breath condensate, sputum, and systemic circulation (Wang et al., 2020). This oxidative stress affects not only the lungs, but also multiple organs throughout the body via the circulatory system (Xiang and Luo, 2024), including the gut. Systemic hypoxia, a key pathological feature of COPD, significantly affects the composition and function of the gut microbiota (Shayista et al., 2025). Experimental studies suggest that hypoxic conditions can damage intestinal epithelial cells and increase intestinal permeability (Zhong et al., 2023), thereby disrupting the balance of the gut microbiota. Furthermore, hypoxia may exacerbate dysbiosis by impairing intestinal immune function. Oxidative stress is prevalent in COPD patients, affecting pulmonary inflammation and the gut via the circulatory system (Fekete et al., 2023; Chen Z. et al., 2022). Research indicates that oxidative stress may further disrupt gut microbial homeostasis (Bajinka et al., 2020). Collectively, these changes may further disrupt gut microbial homeostasis. COPD is associated with characteristic alterations in gut microbial composition, accompanied by an increased abundance of opportunistic pathogens and pro-inflammatory bacteria. Compared with healthy individuals, these microbial alterations reflect a disrupted gut microbial ecosystem (Figure 1). Moreover, COPD patients often require multiple medications, including bronchodilators, corticosteroids, and antibiotics (Li L. et al., 2025). While these drugs positively control pulmonary inflammation and improve respiratory function, they may also negatively impact the gut microbiota. For instance, long-term antibiotic use can lead to dysbiosis, increasing the proportion of harmful bacteria and reducing beneficial ones (Wu et al., 2025). Furthermore, glucocorticoid use may alter gut microbiota composition, affecting its diversity and function (Kang et al., 2024). Long-term medication use may influence gut microbial composition through alterations in intestinal homeostasis, immune regulation and microbial metabolism, thereby further aggravating gut microbiota dysbiosis in COPD patients. Differences in gut microbiota and gut-lung axis between COPD patients and healthy individuals. In COPD patients, systemic hypoxia, oxidative stress and drug interventions act together to impact the composition and function of the gut microbiota. The gut-lung axis theory offers a useful framework through which to understand this complex relationship, revealing the bidirectional communication mechanisms between the gut and the lungs. Collectively, multiple COPD-associated factors trigger gut dysbiosis, demonstrating an intimate link between COPD and gut microbial ecosystem disruption. Therefore, future research should investigate the interactive mechanisms of systemic hypoxia, oxidative stress and drug interventions. With the regulation of gut microbiota at its core, novel intervention strategies should be developed to improve outcomes for COPD patients, offering new therapeutic targets and approaches for clinical treatment. The left panel shows the characteristics of the gut in COPD patients. These include a reduction in the number of bacteria that produce SCFAs, such as Faecalibacterium, Roseburia and Bifidobacterium. There is also a decrease in overall microbial diversity, an increase in opportunistic pathogens such as Escherichia–Shigella, Enterococcus and Streptococcus, elevated pro-inflammatory microbiota and impaired intestinal barrier function. This facilitates the translocation of lipopolysaccharide (LPS) and promotes systemic inflammation. In contrast, the right panel depicts a balanced gut microbiome in healthy individuals, characterised by high diversity, an abundance of SCFA-producing bacteria, and an intact intestinal barrier. The illustration highlights the potential role of the gut-lung axis in COPD pathogenesis. The impact of gut microbiota on COPD Immune modulation The gut microbiota exerts protective immunomodulatory effects on patients with COPD through multiple mechanisms. For example, SCFAs, which are produced by the gut microbiota, exhibit significant anti-inflammatory properties (Chen Y. et al., 2022). These SCFAs can interact with fatty acid receptors (FFARs) on immune cells (Akhtar et al., 2022), thereby suppressing the expression of pro-inflammatory factors such as IL-6, IL-1β and TNF-α. SCFAs may also exert anti-inflammatory effects by inhibiting histone deacetylase complexes and suppressing the nuclear factor kappa B (NF-κB) signalling pathway (van Olst et al., 2021). For instance, a high abundance of Firmicutes and Actinobacteria in COPD patients is significantly correlated with elevated blood inflammatory markers (e.g., IL-6, IL-8 and TNF-α), whereas a higher abundance of Bacteroidetes is associated with improved lung function and lower blood eosinophil counts (Wang et al., 2025). These findings further support the immunomodulatory role of SCFAs in COPD (Li N. et al., 2021). Furthermore, the gut microbiota maintains immune homeostasis by regulating the differentiation and function of immune cells (Song et al., 2020). For instance, certain gut microbiota can modulate the function of regulatory T cells (Tregs), thereby regulating inflammatory responses (Wang et al., 2019). These Tregs are thought to migrate to the lungs, maintaining immune balance and lowering the risk of inflammatory respiratory diseases. However, gut dysbiosis may also exacerbate inflammatory responses in COPD patients via multiple mechanisms. Imbalanced microbiota can disrupt intestinal barrier function, increasing intestinal permeability and facilitating the translocation of microbial products such as LPS into the circulation, thereby promoting immune activation (Sun et al., 2021; Zhu and Fu, 2024). This systemic inflammation can further intensify chronic inflammation in COPD. Furthermore, dysbiosis modulates immune responses by influencing T-cell differentiation and cytokine production, thereby exacerbating pulmonary inflammation and impairing lung function in COPD patients (Gao et al., 2020). Gut dysbiosis may reduce the anti-inflammatory effects of microbial metabolites, including SCFAs, thereby promoting pulmonary inflammation. Collectively, these findings suggest that gut dysbiosis not only weakens anti-inflammatory signalling but may also amplify pulmonary inflammation through coordinated alterations in microbial metabolites, intestinal barrier integrity and immune regulation. Regulatory role of gut microbiota metabolites Gut microbiota-derived metabolites are increasingly recognised as important mediators of COPD pathogenesis. These metabolites including SCFAs, trimethylamine N-oxide (TMAO), tryptophan metabolites and secondary bile acids (SBAs), influence COPD progression by regulating host immune responses and metabolic homeostasis (Okumura and Takeda, 2024; Zhang C. et al., 2021). SCFAs, primarily acetate, propionate and butyrate, are key fermentation products of dietary fibre by the gut microbiota (Then et al., 2020). These metabolites play a crucial role in regulating intestinal barrier function and immune responses. SCFAs have been shown to exert anti-inflammatory effects by binding to G protein-coupled receptors (GPRs), such as GPR41, GPR43 and GPR109A. This inhibits histone deacetylase (HDAC) activity (Cao et al., 2024). For example, in vitro studies have shown that butyrate and propionate can reduce the production of neutrophils stimulated by LPS while decreasing the generation of pro-inflammatory cytokines (e.g., TNF-α and IL-1β) and nitric oxide (NO) (Khudhair et al., 2020). Reduced SCFA availability has been associated with increased disease severity (Li N. et al., 2021), although the immunomodulatory effects of SCFAs may differ according to disease stage, metabolite concentration and host physiological conditions. This may partly explain the inconsistent associations between SCFAs and COPD reported across clinical studies. Differences in dietary intake, patient characteristics, and analytical methods for SCFA quantification are all likely to contribute to the variability in reported findings. TMAO is a small molecule produced by the liver following the metabolism of choline and L-carnitine by gut microbiota (Nishimoto et al., 2022). TMAO is closely associated with the development of various cardiovascular diseases (CVD) and is also considered a potential risk factor for COPD (Li H. et al., 2022, Ghosn et al., 2023). TMAO may contribute to COPD progression by promoting inflammatory signalling pathways and inflammatory responses (Huang et al., 2021). However, circulating TMAO levels are also influenced by dietary patterns, gut microbial composition and host metabolism, suggesting that elevated TMAO may not exclusively reflect COPD-related pathological changes. This complexity should be considered when interpreting the potential role of TMAO as a biomarker or therapeutic target in COPD. Nevertheless, studies indicate that probiotic supplementation, such as Lactobacillus acidophilus (LGG), can modulate the gut microbiota and reduce TMAO levels (Gu et al., 2022; Hijová, 2023), thereby mitigating inflammatory responses. Indole compounds (e.g., indole-3-acetic acid and indole-3-carboxaldehyde), which are produced by the gut microbiota through tryptophan metabolism, play a crucial role in regulating immune responses and intestinal barrier function (Gao H. et al., 2025). These metabolites may alleviate inflammation by binding to the aryl hydrocarbon receptor (AhR) and promoting the secretion of anti-inflammatory cytokines while suppressing pro-inflammatory factors (Poona et al., 2022; Xie et al., 2024). Additionally, indoles indirectly influence metabolic status in COPD patients by enhancing glucagon-like peptide-1 (GLP-1) secretion (Mamic et al., 2021), thereby improving insulin resistance and glucose metabolism. SBAs, such as deoxycholic acid (DCA) and lithocholic acid (LCA), are products of primary bile acid metabolism by gut microbiota (Sanyal et al., 2021; Herlo et al., 2024). These metabolites play a crucial role in regulating lipid metabolism and intestinal barrier function (Hu et al., 2020). SBAs have been proposed to influence intestinal barrier function and immune responses by activating the farnesoid X receptor (FXR) and the G protein-coupled bile acid receptor (TGR5) (Xue et al., 2021). In patients with COPD, altered levels of SBAs are often closely associated with gut microbiota dysbiosis (Liu T. et al., 2023), and this imbalance may further influence the onset and progression of the disease. Together, the gut microbiota and its metabolites play a key role in regulating the pathophysiology of COPD. Key metabolites, such as SCFAs, TMAO, tryptophan metabolites and SBAs (Li S. et al., 2022; Yang and Wu, 2023), influence disease progression and inflammatory severity by modulating immune responses and metabolic homeostasis (Table 2; Figure 2). Collectively, these metabolites provide important mechanistic links between gut microbiota dysbiosis and COPD progression. Nevertheless, the relative contribution of individual microbial metabolites to COPD progression remains difficult to define because microbial metabolism is influenced by multiple host and environmental factors, and current evidence is derived from studies with heterogeneous designs. TABLE 2Major gut microbiota-derived metabolites and their potential roles in COPD.MetaboliteSourceMain targets/pathwaysMajor biological functionsPotential relevance to COPDReferencesSCFAs (acetate, propionate, butyrate)Produced by gut microbial fermentation of dietary fibreGPR41, GPR43, GPR109A; HDAC inhibitionRegulate immune responses, maintain intestinal barrier integrity, suppress inflammationReduced SCFA availability has been associated with increased disease severity Li N. et al. (2021); Then et al. (2020); Cao et al. (2024); Khudhair et al. (2020) TMAOProduced from microbial metabolism of choline and L-carnitine followed by hepatic oxidationInflammatory signalling pathwaysPromotes inflammatory responses and metabolic dysregulationElevated TMAO levels have been associated with COPD progression Nishimoto et al. (2022); Huang et al. (2021) Tryptophan metabolitesProduced by gut microbial tryptophan metabolismAhRRegulate immune homeostasis and intestinal barrier functionMay alleviate inflammation and contribute to immune regulation Gao H. et al. (2025); Poona et al. (2022); Xie et al. (2024) Secondary bile acids (SBAs)Produced by gut microbial metabolism of primary bile acidsFXR, TGR5Regulate lipid metabolism, intestinal barrier function and immune responsesMay contribute to immune and metabolic homeostasis Sanyal et al. (2021); Herlo et al. (2024); Hu et al. (2020); Xue et al. (2021) Abbreviations: SCFAs, short-chain fatty acids; TMAO, trimethylamine N-oxide; HDAC, histone deacetylase; GPR, G protein-coupled receptor; AhR, aryl hydrocarbon receptor; FXR, farnesoid X receptor; TGR5, G protein-coupled bile acid receptor 1; SBAs, secondary bile acids. Major gut microbiota-derived metabolites and their potential roles in COPD. Abbreviations: SCFAs, short-chain fatty acids; TMAO, trimethylamine N-oxide; HDAC, histone deacetylase; GPR, G protein-coupled receptor; AhR, aryl hydrocarbon receptor; FXR, farnesoid X receptor; TGR5, G protein-coupled bile acid receptor 1; SBAs, secondary bile acids. Core mechanisms by which gut microbiota metabolites regulate host immunity and physiological functions. The gut microbiota produces a variety of metabolites, such as SCFAs, tryptophan metabolites, indole compounds, branched-chain fatty acids (BCFAs), bile acids, polyamines, phenolic metabolites and TMAO. These metabolites regulate intestinal barrier function and immunity. SCFAs bind to GPR41, GPR43 and GPR109A receptors, inhibit HDAC, modulate inflammatory responses in macrophages and neutrophils, and influence Treg cell differentiation mediated by dendritic cells, thereby exerting anti-inflammatory effects. Tryptophan is metabolised by the gut microbiota into indole compounds which bind to the AhR receptor, thereby regulating the differentiation balance of CD4+ naive T cells towards Th17/Treg lineages, as well as the polarisation of M0 macrophages towards M1 (pro-inflammatory)/M2 (anti-inflammatory) states. Primary bile acids, transported by ASBT, participate in the regulatory process via FXR/TGR5 receptors. Together, these pathways demonstrate the critical role of gut microbiota metabolites in maintaining immune homeostasis in the host. Barrier dysfunction Patients with COPD often exhibit increased intestinal permeability, which allows gut microbiota and their metabolites to enter the bloodstream and trigger systemic inflammatory responses (Kirschner et al., 2021; Balakin et al., 2025). Gut dysbiosis in COPD is characterised by alterations in microbial composition, which contribute to impaired intestinal barrier integrity (Balderrama-Gómez et al., 2025). This dysbiosis compromises intestinal barrier function and perpetuates and exacerbates pulmonary inflammation by modulating immune responses (Guan et al., 2022). Systemic inflammation arising from intestinal barrier dysfunction affects immune regulation in COPD patients via multiple mechanisms (Figure 3). Bacterial translocation and intestinal barrier impairment in chronic obstructive pulmonary disease (COPD). A clinical study demonstrated that Bifidobacterium therapy significantly improved the composition of the gut microbiota, the function of the gastrointestinal mucosal barrier, and immune function in patients experiencing acute exacerbations of COPD (Song et al., 2024). This suggests that modulating the gut microbiota could effectively improve intestinal barrier function and reduce systemic inflammation in COPD patients. Animal studies indicate that healthy FMT can mitigate emphysema progression by reshaping gut microbial composition and through local and systemic anti-inflammatory effects (Xu et al., 2022; Xiang et al., 2023). These findings further support the role of gut microbiota in maintaining intestinal barrier function. Overall, intestinal barrier dysfunction may represent an important mechanistic link between gut microbiota dysbiosis and COPD progression, as impaired barrier integrity facilitates microbial translocation, systemic inflammation and immune dysregulation. The dysbiosis observed in COPD patients is characterised by a significant reduction in beneficial bacteria (e.g., Bacteroides) and an increase in pathogenic bacteria. This leads to impaired intestinal barrier function. This is accompanied by increased intestinal permeability and elevated zonulin and D-lactate levels, which facilitate the entry of bacterial components and metabolites (e.g., LPS) into the circulation. This triggers systemic inflammation and exacerbates pulmonary inflammation. Alterations in microbial composition also disrupt mucosal immune homeostasis: reduced levels of Bacteroides decrease polysaccharide A (PSA) production, thereby affecting the balance of T cells (e.g., Tregs and Th17s). Concurrently, diminished secretory immunoglobulin A (sIgA) levels and reduced antimicrobial peptides weaken local immune defences. Together, these changes promote elevated levels of inflammatory cytokines (e.g., TNF-α, IL-17 and IFN-γ) via the gut-lung axis, thereby exacerbating airway and pulmonary inflammation in COPD patients. Synergistic effects of environmental and host factors Environmental and host factors influence not only lung health but also the gut microbiota through the gut-lung axis. Environmental factors such as smoking, diet, ageing, medication and infection interact with host factors including genetic background, immune status and metabolic conditions to shape the gut microbiota of COPD patients (Zhu et al., 2024). Smoking is a primary risk factor for COPD and has been associated with alterations in gut microbial composition, which may contribute to gut dysbiosis and immune dysregulation (Li et al., 2021a; Chen et al., 2023). Gut microbiota also produce various signalling molecules and metabolites (Yuan et al., 2024). Poor dietary habits can also disrupt the balance of the gut microbiome: high-fat, high-sugar Western diets are associated with dysbiosis, whereas fibre-rich diets support microbial equilibrium and health (Chen Z. et al., 2025; Elmhadi et al., 2022). As people age, the diversity of their gut microbes typically declines, which is potentially linked to reduced immune function in the elderly and can further exacerbate COPD pathology (Durack and Lynch, 2019). Meanwhile, the long-term use of antibiotics and glucocorticoids in COPD patients, while effectively controlling pulmonary inflammation, may also disrupt the balance of gut microbiota and induce dysbiosis (Yang-Jensen et al., 2025). Respiratory infections commonly trigger COPD exacerbations (Huang and Shi, 2019). These infections affect not only the lungs but also alter gut microbial homeostasis through gut-lung interactions. A person’s genetic background, immune status and metabolic condition can also influence the composition and function of their gut microbiota (Zhang Y. et al., 2021). COPD patients often exhibit immune dysfunction, which may contribute to gut dysbiosis and disease progression (Ye et al., 2023). Furthermore, metabolic disorders such as obesity and diabetes are closely linked to gut microbiota composition (Li et al., 2021b), and may further aggravate COPD pathology by affecting the gut microbiome (Figure 4). Environmental and host factors jointly shape the gut microbiome and influence lung health via the gut-lung axis. These findings suggest that environmental and host factors do not act independently but may interact through the gut microbiota, collectively influencing immune regulation and inflammatory responses during COPD progression. The structure and function of the gut microbiota are influenced by environmental factors (such as smoking, diet, ageing, medication use and infection) and host factors (including genetics, immune status and metabolic levels). This microbiota produces a variety of signalling molecules and metabolites, including SCFAs, bile acids, neurotransmitters, enteric hormones, endocannabinoids and TMAO. These substances can influence the physiological and inflammatory states of distant organs, including the lungs, via systemic immune regulatory pathways. Gut microbiota-based intervention strategies for COPD Dietary adjustment A high-fibre diet is a key strategy for regulating gut microbiota (Bell et al., 2022). Dietary fibre is the main nutrient for intestinal bacteria, which ferment it to produce SCFAs that are active physiologically (Macia et al., 2021; Fan et al., 2021). These metabolites positively affect intestinal function and influence lung health via the bloodstream (Lu et al., 2021). Research indicates a negative correlation between high-fibre diets and COPD incidence, with adequate dietary fibre intake reducing systemic and airway inflammation levels (Brennan et al., 2022; Bailey et al., 2023; Jiang et al., 2023). Furthermore, studies on COPD animal models have demonstrated that high-fibre diets can minimise inflammatory responses and delay the pathological changes associated with emphysema progression (Millares and Monso, 2022). Although animal studies support the potential benefits of a high-fibre diet in COPD, evidence from randomized controlled clinical trials remains limited. Probiotics, prebiotics Probiotics and prebiotics are another effective way of regulating gut microbiota and improving microecological imbalances (Luo et al., 2021). Probiotics are live microorganisms that are beneficial to the host and can directly supplement beneficial bacterial strains, such as lactobacilli and bifidobacteria (Shen et al., 2024; Gao et al., 2024; Du et al., 2023). Studies suggest that probiotic supplementation can alleviate dysbiosis in COPD patients, lower serum inflammatory marker levels and improve quality of life (Su et al., 2024). Prebiotics, on the other hand, selectively stimulate the growth of beneficial bacteria such as inulin and fructooligosaccharides (Shanmugasundaram Prema et al., 2025). Prebiotic supplementation selectively promotes the growth of beneficial gut microorganisms, thereby supporting microbial homeostasis (Wan et al., 2023). However, differences in probiotic strains, dosages and treatment protocols, together with the generally small sample sizes of existing studies, make it difficult to compare outcomes across studies and limit the standardization of clinical application. FMT Multiple studies using animal models support the potential of FMT in the treatment of COPD. For example, Li et al. transplanted faecal microbiota from healthy controls and COPD patients at different stages of the disease into recipient mice. The results showed that the mice that received microbiota from COPD patients exhibited more severe pulmonary inflammation. Following additional smoke exposure, these mice demonstrated impaired lung function, severe emphysematous changes, increased mucus secretion and airway hyperresponsiveness (Li N. et al., 2021). Furthermore, Budden et al. utilised a smoke-induced COPD mouse model and found that FMT reduced COPD-associated inflammation and alveolar destruction, improving lung function and alleviating intestinal inflammation and systemic immune dysregulation (Budden et al., 2024). These studies provide a foundation for the application of FMT in COPD treatment. Although clinical studies of FMT in COPD treatment remain relatively scarce, existing research has yielded positive outcomes. For example, one study found that FMT treatment increased gut microbiota diversity, reduced inflammatory marker levels and improved quality of life in COPD patients (Ye et al., 2025). These preliminary findings suggest that FMT may improve the pathological status and prognosis of COPD patients by reshaping the gut microbiota and mitigating inflammatory responses. At a mechanistic level, FMT may exert therapeutic effects by restoring gut microbial homeostasis, modulating microbial metabolites and improving intestinal barrier function (Hua et al., 2022; Xie et al., 2025; Tang et al., 2024). Although FMT has yielded encouraging findings in preclinical and early clinical studies, its clinical application remains limited by the lack of large-scale randomised controlled trials and standardised donor selection and transplantation protocols. Additional studies are required to confirm its long-term efficacy and safety in COPD treatment. Phage therapy Bacteriophages are viruses that infect bacteria specifically, and are capable of shaping bacterial communities by inducing lysis of bacterial cells and influencing bacterial phenotypes (Sugai et al., 2023; Lin et al., 2025). Compared to traditional antibiotics, phage therapy has the advantage of being able to target specific bacteria with precision, enabling it to modulate the gut microbiota and eliminate various drug-resistant bacteria (Xu et al., 2023). A significant benefit of this therapy is its specificity towards the targeted bacteria, with minimal interference with other gut microorganisms (Choy and Freedberg, 2020). Phage therapy can be used as an alternative or complementary treatment to antibiotics (Cai et al., 2018). While research on phage therapy for COPD is limited, existing studies suggest its potential in regulating gut dysbiosis and alleviating inflammation (Bao et al., 2022). For example, studies have found that phage therapy can improve the balance of microorganisms in the gut by reducing the abundance of harmful bacteria while increasing the number of beneficial ones (Febvre et al., 2019). Furthermore, phage therapy may exert anti-inflammatory effects by modulating gut microbial composition and its metabolites, thereby contributing to gut-lung immune homeostasis (Table 3; Figure 5). TABLE 3Microbiota-targeted COPD interventions: evidence and limitations.InterventionEvidence typeMajor findingsMain limitationsReferencesDietary adjustment (high-fibre diet)Animal studiesHigh-fibre diets are associated with a lower risk of COPD and reduced systemic and airway inflammation. Animal studies suggest that dietary fibre supplementation delays emphysema progressionEvidence from randomized controlled trials (RCTs) remains limited Brennan et al. (2022); Bailey et al. (2023); Jiang et al. (2023); Millares and Monso (2022) Probiotics and prebioticsClinical studiesProbiotic and prebiotic supplementation may improve gut microbiota composition, reduce inflammatory markers and improve quality of life in patients with COPD.Small sample sizes, heterogeneous probiotic strains, dosages and treatment protocols, and lack of standardized formulations Luo et al. (2021); Shen et al. (2024); Du et al. (2023); Su et al. (2024) Faecal microbiota transplantation (FMT)Animal studies; early clinical studiesFMT reduces pulmonary inflammation and emphysema progression in animal models. Preliminary clinical studies suggest improvements in gut microbiota diversity, inflammatory status and quality of lifeLack of large-scale randomized controlled trials and standardized donor selection and transplantation protocols Budden et al. (2024); Ye et al. (2025) Phage therapyAnimal studies; Preclinical studiesPhage therapy may selectively modulate gut microbiota and alleviate inflammation through targeted elimination of pathogenic bacteriaClinical evidence remains limited, and further studies are required to determine its efficacy, safety and optimal treatment protocols Xu et al. (2023); Choy and Freedberg (2020); Bao et al. (2022) Abbreviations: COPD, chronic obstructive pulmonary disease; RCT, randomized controlled trial; FMT, fecal microbiota transplantation. Microbiota-targeted COPD interventions: evidence and limitations. Abbreviations: COPD, chronic obstructive pulmonary disease; RCT, randomized controlled trial; FMT, fecal microbiota transplantation. Modulating gut microbiota through multiple intervention strategies to improve COPD. While phage therapy shows promise in the treatment of COPD, further research is required to evaluate its long-term efficacy and safety. Future research should focus on the following areas: Firstly, more randomised controlled trials should be conducted to validate the efficacy and safety of phage therapy across different stages of COPD progression. Secondly, determining the optimal dosage, administration route and treatment cycle for phage therapy. Third, improving our understanding of its mechanisms of action, particularly its long-term effects on gut microbiota metabolites and immune responses. The diagram illustrates the pathways through which dietary modification, probiotic/prebiotic supplementation, FMT, and phage therapy exert effects on the gut-lung axis. High-fiber diets, metabolized by gut microbiota to produce short-chain fatty acids (such as acetate, propionate, and butyrate), reduce the risk of developing COPD. Probiotics and prebiotics promote gut homeostasis by enhancing intestinal epithelial barrier function, increasing beneficial bacteria, and reducing harmful bacteria. Fecal microbiota transplantation involves transferring processed functional microbiota from healthy donors into patients’ intestines to restore disrupted gut microbiota and reestablish intestinal microecological balance. Specific phages can be employed to target and eliminate harmful bacteria while enriching beneficial ones in the gut. This process regulates intestinal metabolites and modulates immune status. Current challenges and future prospects Research limitations Although initial progress has been made in current research on the relationship between gut microbiota and COPD, significant limitations remain. Firstly, many studies have small sample sizes and insufficient statistical power, which can lead to biased results that are difficult to generalise to broader populations. For instance, one study only included 40 COPD patients, which could restrict the generalisability of its findings. Secondly, some studies fail to adequately control for potential confounding factors, such as antibiotic use and glucocorticoid dosage. Such factors are prevalent among COPD patients and can significantly impact the composition and stability of the gut microbiota, thereby hindering accurate assessments of dysbiosis risk. Furthermore, many studies do not distinguish between different COPD phenotypes or disease stages, which can obscure microbial differences across distinct subgroups. While existing research suggests a strong link between gut dysbiosis and COPD onset and progression, the exact nature of this relationship is unclear. Most current studies remain at the level of correlation analysis and lack experimental validation, which makes it difficult to determine whether gut dysbiosis is a precursor to COPD or a consequence of disease progression. Additionally, the specific mechanisms underlying the gut-lung axis are still in the early stages of research and require further systematic investigation. Secondly, the composition of the gut microbiota is complex and our understanding of the interactions between the gut microbiota and the host is limited. Any localised changes in the gut microbiota may impact host health, but current research methods and technologies are insufficient to fully elucidate these intricate interaction mechanisms. Frontier directions Multi-omics technologies integrate data from multiple levels of microbiomics, metabolomics and transcriptomics, providing deeper insights into the complex relationship between the gut microbiota and COPD. For example, metagenomic sequencing revealed significant differences in species composition and abundance between COPD patients and healthy individuals (Bowerman et al., 2020). COPD patients exhibit reduced gut microbial diversity (Gao Y. et al., 2025), with significant enrichment of specific genera, such as Purpureaphilidae and Veillonella, and depletion of beneficial bacteria, such as Ruminellaceae and Bifidobacterium. These alterations disrupt intestinal microbial balance and may impact lung health via the gut-lung axis. Metabolomics analysis has also revealed changes in gut metabolites in COPD patients. The study found decreased levels of gut metabolites such as SCFAs (Wallenborn and Vonaesch, 2022), as well as elevated levels of certain metabolites related to inflammation. These metabolic changes may influence the pathological progression of COPD by modulating the host’s immune response (Song et al., 2023; Yang et al., 2022). Transcriptomics research has focused on alterations in host gene expression. The research indicates that the functional activities of gut microbial genes in COPD patients differ significantly from those of healthy controls in terms of biological processes, cellular components and molecular functions (Poto et al., 2022). These altered gene functions may interact with changes in the composition of the gut microbiota to influence the health status of the host. Advances in AI technology mean that researchers can now use machine learning algorithms to predict the links between characteristics of the gut microbiota and COPD phenotypes. By integrating multi-omics data, AI models can identify the specific microbial features and metabolic biomarkers that are linked to the pathogenesis of COPD. These models enhance our understanding of the complex relationship between gut microbiota and COPD, offering new avenues for personalised treatment. For example, personalised microbial fingerprint profiles generated through machine learning can predict disease progression and treatment response in COPD patients. These predictive models provide clinicians with crucial decision support, helping them to optimise treatment plans and enhance therapeutic outcomes. Personalised treatment strategies based on gut microbiota, such as probiotics and phage therapy, offer novel approaches to COPD management. Probiotic therapy regulates the balance of gut microbiota by supplementing beneficial strains such as bifidobacteria and lactobacilli (Xu and Wang, 2025; Liu Z. L. et al., 2023; Morniroli et al., 2021; Afrin et al., 2021). Studies indicate that probiotics can improve lung function, reduce inflammatory markers and enhance quality of life in COPD patients (Zhou et al., 2024). Phage therapy restores gut microbiome equilibrium by selectively eliminating harmful bacterial species (Koning et al., 2023; Kazantseva et al., 2023). Compared to antibiotics, phage therapy is more specific and has fewer side effects (Luo et al., 2024). Research suggests that phage therapy has great potential in reshaping the structure of the gut microbiota and alleviating systemic inflammation (Cao et al., 2025). In summary, multi-omics integration technologies offer new tools for systematically unravelling the intricate mechanisms connecting gut microbiota and COPD. The application of AI technology offers new ways of predicting the links between characteristics of the gut microbiota and COPD phenotypes. The development of personalised probiotic and phage therapies provides new COPD treatment strategies. Further research into the potential applications of these technologies in COPD treatment is needed to provide new scientific evidence and clinical pathways for the precision diagnosis and therapy of COPD. Conclusion Further evidence suggests that the gut microbiota influences the onset and progression of COPD through the gut-lung axis. Patients with COPD often exhibit reduced diversity of gut microbiota, decreased levels of beneficial bacteria and increased levels of pathogenic bacteria, as well as compromised intestinal barrier function. The combined effects of systemic hypoxia, oxidative stress, drug interventions and environmental exposures promote dysbiosis and the translocation of microbial products, thereby exacerbating systemic inflammatory responses. This disrupts pulmonary immune homeostasis and intensifies tissue damage. The gut microbiota and their metabolites, such as SCFAs, TMAO, tryptophan metabolites and SBAs, play a key role in linking gut dysbiosis to immune dysregulation, metabolic disorders and COPD severity. Despite advances in research, the current understanding remains largely correlational, with significant heterogeneity across studies due to differences in patient populations, disease phenotypes, sequencing methodologies, smoking status, medication exposure and other potential confounding factors. In addition, substantial interindividual variability in gut microbiota composition further complicates the interpretation and comparison of existing findings. Interventions targeting the gut microbiota, including dietary modifications, probiotics, prebiotics, FMT and phage therapy, have demonstrated potential in animal models and early clinical trials, though their efficacy and long-term safety require further validation. In addition, validated biomarkers for identifying patients who are most likely to benefit from microbiota-targeted therapies are still lacking, which further limits their clinical translation. Moreover, most available evidence is derived from cross-sectional studies or animal models, whereas longitudinal and mechanistic human studies remain limited. Future research should integrate multi-omics technologies, advanced computational models, high-quality longitudinal cohort studies and mechanistic human studies to clarify the causal relationship between gut dysbiosis and COPD. A deeper understanding of the gut-lung axis mechanism could lead to more precise intervention strategies based on gut microbiota, providing new theoretical foundations and therapeutic approaches for personalised COPD management and improved prognosis.